HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Core Insights - The combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) has been approved by the China National Medical Products Administration (NMPA) for treating patients with locally advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC) with MET amplification after progression on EGFR TKI therapy [1][2][3] - This combination treatment is the only all-oral option available for these patients, providing a chemotherapy-free approach [1][3] - The SACHI Phase III trial demonstrated a 66% reduction in the risk of disease progression or death compared to platinum-based chemotherapy, with a median progression-free survival (PFS) of 8.2 months for the combination versus 4.5 months for chemotherapy [1][3][12] Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery and commercialization of targeted therapies for cancer and immunological diseases [15] - The approval of the ORPATHYS and TAGRISSO combination marks a significant milestone in HUTCHMED's mission to address MET-driven progression in NSCLC patients [3][15] - AstraZeneca collaborates with HUTCHMED to market both ORPATHYS and TAGRISSO in China, enhancing the reach of this new treatment option [3][15] Industry Context - Lung cancer is the leading cause of cancer death, with NSCLC accounting for 80-85% of cases [5] - Approximately 30-40% of NSCLC patients in Asia have EGFR mutations, highlighting the need for effective treatment options [5][6] - MET amplification is a common mechanism of acquired resistance to EGFR TKI therapy, affecting 15-50% of patients who experience disease progression [11][12]